Genenta Science S.P.A. ADR (GNTA)

$0.88 -0.10 (-10.28%)
Market Cap 18.89M
Revenue (ttm) 0.00
Net Income (ttm) -9.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 270,700
Avg Vol 1,283,844
Day's Range N/A - N/A
Shares Out 19.15M
Stochastic %K 4%
Beta 0.59
Analysts Strong Sell
Price Target $7.00

Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and i...

Industry: Biotechnology
Sector: Healthcare
Phone: 39 02 26434681
Address:
Via Olgettina No. 58, Milan, Italy
123MONEYGUY
123MONEYGUY Feb. 3 at 8:07 PM
$GNTA IT FAILED TO ATTRACT INSTITUTIONAL TRADERS
0 · Reply
theBigDollarski
theBigDollarski Feb. 3 at 7:41 PM
$GNTA good thing they announced that strategic transformation before the stock really fell apart.....
0 · Reply
123MONEYGUY
123MONEYGUY Feb. 3 at 6:28 PM
$GNTA garbage disposal
0 · Reply
mcewing
mcewing Feb. 3 at 3:40 PM
$GNTA I guess the lights are out on this one
0 · Reply
mcewing
mcewing Jan. 30 at 5:17 PM
$GNTA market cap $19 mill....CAsh $33 mill....why is this falling ?
0 · Reply
Bcity
Bcity Jan. 30 at 1:30 AM
$GNTA as soon as it drops doen watchers leave 😂😂😂 people are like roaches where food is)))
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 29 at 10:32 PM
$GNTA BEEN ME WHOLE TIME OFF 1.14************************************ 86 ILLION VOLUME OFF THE BOOKS
1 · Reply
theBigDollarski
theBigDollarski Jan. 29 at 3:22 PM
$GNTA doubled down @ 1.09......Guns and doses.
1 · Reply
123MONEYGUY
123MONEYGUY Jan. 29 at 2:55 PM
$GNTA no body is buying boonubo.monkey test
0 · Reply
DARKP00L
DARKP00L Jan. 28 at 10:39 PM
$XHLD $GNTA $MOVE.X $NUWE
0 · Reply
Latest News on GNTA
Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments

Jan 27, 2026, 12:45 PM EST - 7 days ago

Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

Jan 27, 2026, 3:00 AM EST - 7 days ago

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

Genenta Science Provides Update on CEO Ownership

Dec 19, 2025, 2:30 AM EST - 6 weeks ago

Genenta Science Provides Update on CEO Ownership

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Nov 24, 2025, 4:00 AM EST - 2 months ago

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating

Oct 27, 2025, 5:31 PM EDT - 3 months ago

Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Oct 26, 2025, 8:30 PM EDT - 3 months ago

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Oct 24, 2025, 4:00 AM EDT - 3 months ago

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

Jul 1, 2025, 5:00 AM EDT - 7 months ago

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

May 8, 2025, 7:00 AM EDT - 9 months ago

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

May 7, 2025, 7:00 AM EDT - 9 months ago

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Apr 15, 2025, 5:00 AM EDT - 10 months ago

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

Mar 19, 2025, 9:28 AM EDT - 11 months ago

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Jan 28, 2025, 8:01 AM EST - 1 year ago

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

Jan 9, 2025, 6:00 AM EST - 1 year ago

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Jan 8, 2025, 3:17 PM EST - 1 year ago

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Genenta Welcomes New Directors John L. Cantello, Lauren H.

May 6, 2024, 6:25 AM EDT - 1 year ago

Genenta Welcomes New Directors John L. Cantello, Lauren H.

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Feb 8, 2024, 5:00 AM EST - 2 years ago

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Genenta to Present at Upcoming Scientific and Investor Conferences

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Genenta to Present at Upcoming Scientific and Investor Conferences

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Jul 28, 2023, 3:00 AM EDT - 2 years ago

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Jun 29, 2023, 7:00 AM EDT - 2 years ago

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Apr 26, 2023, 7:00 AM EDT - 3 years ago

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

Apr 3, 2023, 7:00 AM EDT - 3 years ago

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Mar 2, 2023, 6:45 AM EST - 3 years ago

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Feb 7, 2023, 7:00 AM EST - 3 years ago

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Nov 7, 2022, 8:05 AM EST - 3 years ago

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Genenta Provides First Half 2022 Business Update and Financial Results

Oct 24, 2022, 7:30 AM EDT - 3 years ago

Genenta Provides First Half 2022 Business Update and Financial Results

Genenta to Present at Upcoming Investor Conferences

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Genenta to Present at Upcoming Investor Conferences

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Jul 25, 2022, 6:00 AM EDT - 3 years ago

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

May 13, 2022, 7:30 AM EDT - 4 years ago

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

May 9, 2022, 7:30 AM EDT - 4 years ago

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

May 4, 2022, 4:30 PM EDT - 4 years ago

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

May 4, 2022, 7:30 AM EDT - 4 years ago

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

May 2, 2022, 4:30 PM EDT - 4 years ago

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

Genenta Announces Nomination of Mark A. Sirgo as Chair

Apr 27, 2022, 7:30 AM EDT - 4 years ago

Genenta Announces Nomination of Mark A. Sirgo as Chair

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Apr 20, 2022, 7:30 AM EDT - 4 years ago

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Mar 9, 2022, 7:46 AM EST - 4 years ago

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Genenta to Participate at Upcoming Investor Conferences

Feb 24, 2022, 7:30 AM EST - 4 years ago

Genenta to Participate at Upcoming Investor Conferences

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Dec 17, 2021, 4:15 PM EST - 4 years ago

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Genenta Announces Pricing of Upsized Initial Public Offering

Dec 14, 2021, 10:36 PM EST - 4 years ago

Genenta Announces Pricing of Upsized Initial Public Offering

123MONEYGUY
123MONEYGUY Feb. 3 at 8:07 PM
$GNTA IT FAILED TO ATTRACT INSTITUTIONAL TRADERS
0 · Reply
theBigDollarski
theBigDollarski Feb. 3 at 7:41 PM
$GNTA good thing they announced that strategic transformation before the stock really fell apart.....
0 · Reply
123MONEYGUY
123MONEYGUY Feb. 3 at 6:28 PM
$GNTA garbage disposal
0 · Reply
mcewing
mcewing Feb. 3 at 3:40 PM
$GNTA I guess the lights are out on this one
0 · Reply
mcewing
mcewing Jan. 30 at 5:17 PM
$GNTA market cap $19 mill....CAsh $33 mill....why is this falling ?
0 · Reply
Bcity
Bcity Jan. 30 at 1:30 AM
$GNTA as soon as it drops doen watchers leave 😂😂😂 people are like roaches where food is)))
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 29 at 10:32 PM
$GNTA BEEN ME WHOLE TIME OFF 1.14************************************ 86 ILLION VOLUME OFF THE BOOKS
1 · Reply
theBigDollarski
theBigDollarski Jan. 29 at 3:22 PM
$GNTA doubled down @ 1.09......Guns and doses.
1 · Reply
123MONEYGUY
123MONEYGUY Jan. 29 at 2:55 PM
$GNTA no body is buying boonubo.monkey test
0 · Reply
DARKP00L
DARKP00L Jan. 28 at 10:39 PM
$XHLD $GNTA $MOVE.X $NUWE
0 · Reply
StockScanners
StockScanners Jan. 28 at 7:50 AM
$GNTA idea for a pullback play, nice run to $2.60’s
0 · Reply
theBigDollarski
theBigDollarski Jan. 28 at 4:43 AM
$GNTA so 57MM shares traded on a company with 14MM float. Nope, doesn't pass the sniff test
0 · Reply
DARKP00L
DARKP00L Jan. 28 at 2:46 AM
$XHLD $GNTA $MOVE.X $NUWE
1 · Reply
MadMaverick
MadMaverick Jan. 27 at 9:15 PM
⚡WATCHLIST RECAP 01/27/2026⚡ ✅ $XTKG | +10% max profit ✅ $PHGE | +26% max profit ❌ $GNTA & $CYN did not hit entry point. Follow to get daily access to my watchlist and trade ideas.
0 · Reply
peepthestamp
peepthestamp Jan. 27 at 9:08 PM
$GNTA
0 · Reply
SHEEPWOLF
SHEEPWOLF Jan. 27 at 8:23 PM
$GNTA Could be a big mover in after hours--big money been loading all morning, back over $2.00 and the run resumes soon. 🌛MOON AND BEYOND, LET'S GO! NEWS: https://finviz.com/news/287825/genenta-announces-strategic-transformation-into-a-biotech-defense-aerospace-and-national-security-industrial-consolidator
2 · Reply
dixiebull
dixiebull Jan. 27 at 8:19 PM
$GNTA nice! @ProtraderJS sick as a dog but still on it for us
0 · Reply
SHEEPWOLF
SHEEPWOLF Jan. 27 at 8:08 PM
$GNTA on the move. It did hit$2.60 in early premarket
0 · Reply
Ron_Burn
Ron_Burn Jan. 27 at 8:06 PM
$GNTA thinking about scaling in
0 · Reply
DARKP00L
DARKP00L Jan. 27 at 7:38 PM
$OPTT If you’re not in our community sever, you’re missing out on these alerts! [Link in Bio] $XHLD We $GNTA Stay $MOVE.X Lit $NUWE #pennystock #tradeideas #stockmarket #lowfloat #stockstotrade #stockscanner #tradinginsights
0 · Reply
SHEEPWOLF
SHEEPWOLF Jan. 27 at 7:29 PM
$GNTA First Industrial Integration- ATC is a private company operating as a high-precision manufacturer of tactical rifles and special-forces weapon systems, and competition-grade sporting firearms. Genenta has entered into a binding agreement according to which it will provide funding for ATC through a series of reserved capital increases, via a performance-based and staged acquisition to support operations with the ultimate goal of owning a controlling position in ATC upon the achievement of defined performance milestones. The transaction has received the required clearance under the Golden Power regulatory framework.
0 · Reply
123MONEYGUY
123MONEYGUY Jan. 27 at 4:48 PM
$GNTA we refused to buy. AC MILANO
0 · Reply